Atacicept (Vera): BAFF+APRIL Dual Inhibitor for IgAN Phase 3
Vera's Atacicept: TACI-Fc fusion neutralizing BAFF+APRIL. ORIGIN Ph2b (Kidney Int 2024) UPCR -46%. Ph3 interim -42% PBO-adjusted. PDUFA target Jul 2026.
Introduction: Hitting B-Cell Cytokines from Both Sides
In IgAN, APRIL-only antibodies (Sibeprenlimab, Zigakibart) lead the B-cell targeting strategy at FDA. Vera Therapeutics' Atacicept, a TACI-Fc fusion protein that neutralizes both BAFF and APRIL, offers deeper upstream suppression of Gd-IgA1 production. ORIGIN Phase 2b (Kidney Int 2024) showed UPCR −46%, and Phase 3 interim reached placebo-adjusted −42%, with a July 2026 PDUFA target[1][2].
1. Compound Profile
| Item | Detail |
|---|---|
| Generic name | Atacicept |
| Origin | ZymoGenetics → Merck Serono (EMD Serono) → Vera Therapeutics (licensed 2021) |
| Modality | TACI-Fc fusion (human TACI ectodomain + IgG1 Fc), BAFF + APRIL dual neutralization |
| Dose | 150 mg SC QW |
| Target approval | IgAN (ORIGIN Phase 3), PDUFA target Jul 2026 |
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. BAFF/APRIL Biology in IgAN
- APRIL: IgA plasma cell survival, IgA1 class switching, Gd-IgA1 overproduction driver
- BAFF: upstream B-cell survival, maturation, T-dependent antibody responses
- Dual inhibition rationale: captures BAFF-dependent B-cell compartments that escape APRIL-only blockade, adding depth to Gd-IgA1 suppression
- Trade-off: higher risk of hypogammaglobulinemia and serious infections vs APRIL-alone
3. Mechanism: Differentiation vs Sibeprenlimab
| Agent | Target | Immune breadth | Dosing |
|---|---|---|---|
| Atacicept | BAFF + APRIL dual | Pan-B + plasma cells | SC QW |
| Sibeprenlimab | APRIL only | IgA plasma cells | SC Q4W |
| Zigakibart (BION-1301) | APRIL only (IgG4) | Similar | SC Q2W |
Clinical trade-off: Atacicept leans on effect size; Sibeprenlimab wins on dosing convenience and narrower safety profile (no head-to-head data).
4. Clinical Evidence
4-1. ORIGIN Phase 2b[3]
- Design: IgAN, 150 mg SC QW vs placebo
- 36-week UPCR: placebo-adjusted −46% (150 mg arm), eGFR stabilization
- Gd-IgA1: significantly reduced
- Lafayette R et al., Kidney Int 2024;105(6):1306-1315 (PMID 38552841, Barratt J senior author)
4-2. ORIGIN Phase 3 (NCT04716231)[1]
- Design: randomized DB placebo-controlled, IgAN n≈376, 150 mg SC QW
- Primary: 36-week UPCR change
- Interim (Jun 2024): placebo-adjusted UPCR −42% (p<0.0001), Gd-IgA1 −60%, hematuria improvement
- eGFR slope: 2025 H2 readout
- BLA: Q4 2025; PDUFA target Jul 2026 (accelerated path)
4-3. PIONEER Phase 2 (NCT06373237)
- FSGS / MCD, started 2024 — expansion to non-Gd-IgA1-driven glomerular diseases
5. Regulatory
- FDA BLA: Q4 2025 filing, PDUFA Jul 2026
- Full approval: gated on eGFR slope
- EMA / PMDA: limited public information
6. SLE Failure → IgAN Pivot
- APRIL-SLE (2011-2015): SLE, flare reduction trend but primary EP missed; high-dose arm halted due to serious infections/deaths (Ann Rheum Dis 2015;74(11), PMID 24951103)
- Pivot rationale: well-defined BAFF/APRIL-Gd-IgA1 axis in IgAN, narrower renal-immune scope, optimized 150 mg QW dose
7. Competitive Landscape (IgAN)
| Agent | MoA | Phase | Primary EP |
|---|---|---|---|
| Atacicept | BAFF/APRIL dual | Phase 3 (ORIGIN), PDUFA Jul 2026 | UPCR −42% adjusted |
| Sibeprenlimab | anti-APRIL | FDA accelerated Nov 2025 | UPCR −51.2% |
| Zigakibart (BION-1301) | anti-APRIL | Phase 3 (BEYOND) | UPCR −60% (Ph1/2) |
| Iptacopan | Factor B | FDA Aug 2024 accelerated | UPCR −38% + eGFR |
| Sparsentan | ETA/AT1R | Full approval | UPCR −50% |
| Atrasentan | ETA-selective | Accelerated Apr 2025 | UPCR −36.1% |
8. Preclinical & Biomarkers
- Serum BAFF / APRIL: direct response markers
- Gd-IgA1: disease biomarker, −60% in Atacicept arm
- Total IgG / IgA / IgM: hypogammaglobulinemia monitoring
- UPCR / eGFR slope: clinical endpoints
9. Points to Watch
- ORIGIN 24-month eGFR slope — gates full approval
- FDA approval timing (PDUFA Jul 2026) — second-in-class to Sibeprenlimab but larger effect size
- PIONEER FSGS/MCD expansion under Vera solo development
- Head-to-head dynamics with Sibeprenlimab / Zigakibart
- Long-term infection risk from BAFF suppression — hypogammaglobulinemia management
References
1. Vera Therapeutics. Pipeline — Atacicept in IgAN. Vera Pipeline / ClinicalTrials.gov: NCT04716231
2. Vera Therapeutics. ORIGIN Phase 3 Interim Analysis Topline Results. June 2024. Vera IR
3. Lafayette R, et al. Efficacy and Safety of Atacicept in IgA Nephropathy (ORIGIN Phase 2b). Kidney Int. 2024;105(6):1306-1315. PubMed 38552841
4. Isenberg D, et al. Efficacy and safety of atacicept for prevention of flares in patients with SLE (APRIL-SLE). Ann Rheum Dis. 2015;74(11):2006-2015. PubMed 24951103
5. PIONEER-FSGS/MCD — ClinicalTrials.gov: NCT06373237